Skip to main content

Advertisement

Log in

Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26(30):4952–4957. doi:10.1200/JCO.2007.15.3429

    Article  PubMed  Google Scholar 

  2. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Duhrsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Briere J, Salles G, Moskowitz CH, Glass B (2012) Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20 (+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 30(36):4462–4469. doi:10.1200/JCO.2012.41.9416

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344–349. doi:10.1111/j.1365-2141.2009.07626.x

    Article  PubMed  CAS  Google Scholar 

  4. Thieblemont C, Delfau-Larue MH, Coiffier B (2012) Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol 2012:861060. doi:10.1155/2012/861060

    PubMed  PubMed Central  Google Scholar 

  5. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11(16):5984–5992. doi:10.1158/1078-0432.ccr-05-0577

    Article  PubMed  CAS  Google Scholar 

  6. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925–1932. doi:10.1038/leu.2008.174

    Article  PubMed  CAS  Google Scholar 

  7. Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA (2013) The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol. doi:10.1002/ajh.23577

    Google Scholar 

Download references

Acknowledgments

We thank C. Steffens from radiologie.zentrum.nordharz, Goslar for the CT scan Fig. 1c.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nikolai Schuelper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schuelper, N., Flohr, A., Trümper, L. et al. Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide. Ann Hematol 93, 1929–1930 (2014). https://doi.org/10.1007/s00277-014-2071-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2071-7

Keywords

Navigation